The ISG assessment highlights Indegene’s deep domain expertise, proprietary technology stack, and expanding use of AI and GenAI to drive more integrated, data-led commercial execution across the life sciences value chain
The lens received U.S. Food and Drug Administration (FDA) market authorization via the De Novo pathway in late 2025
_256_384.png)
The company plans a phased expansion across India, focusing initially on metro cities and early-adoption hubs
Developed for today’s fast-paced, visually demanding lifestyles, the lenses are built on ZEISS NeurOptix technology
At the center of the collapse is opposition from the Federal Trade Commission
ExellenS applies optimized facility designs, equipment, and processes across all sites to ensure equivalency and speed
FDA authorization was based on two years of clinical study data demonstrating that Essilor Stellest lenses significantly slowed myopia progression compared to single-vision control lenses
ISG acknowledged Indegene's strengths in implementing holistic creative workflows, interoperability via robust integration with tech ecosystems
Next-generation lens features purely refractive design, delivering uninterrupted high-quality vision with high best-in-category contrast & low-light performance
The company is already marketing the 4 mg and 10 mg strengths
Subscribe To Our Newsletter & Stay Updated
